27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
The study cohort included 568 patients (289 [50.9%] men; mean [SD] age, 70.5 [16.1] years) who died in the hospital or were discharged to hospice. 1 key finding →
Design: cohort study Participants: 568 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The relationships between alcohol consumption and dementia and cognitive decline were investigated in a systematic review including meta-analyses of 15 prospective studies. 4 key findings →
Design: systematic review Participants: 14,646 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this study, several factors, mostly modifiable, were associated with a higher risk of YOD. 4 key findings →
Design: cohort Participants: 356,052 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
4024 articles were identified, and 74 were included in our narrative synthesis. 2 key findings →
Design: meta-analysis Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The diabetes attributable risk for dementia of 8.8% suggests that diabetes may have contributed to the clinical syndrome in a substantial proportion of all dementia patients. 2 key findings →
Design: cohort study Participants: 126 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The number of years of formal education completed by individuals is positively correlated with their cognitive function throughout adulthood and predicts lower risk of dementia late in life. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Sleep fragmentation in older adults is associated with incident AD and the rate of cognitive decline. 5 key findings →
Design: cohort study Participants: 97 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our aim was to test the association of vascular risk factor exposure in midlife with progression of MRI markers of brain aging and measures of cognitive decline. 1 key finding →
Design: cohort study Participants: 1,352 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
However, the advisory did not apply to conventional antipsychotic medications; the risk of death with these older agents is not known. 1 key finding →
Design: cohort study Participants: 22,890 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
When identifying participants with abnormal CSF Aβ42/40 in the whole cohort, plasma IP-MS-WashU Aβ42/40 showed significantly higher accuracy (area under the receiver operating characteristic curve [AUC], 0.86; 95% CI, 0.81-0.90) than LC-MS-Arc Aβ42/40, IA-Elc Aβ42/40, IA-EI Aβ42/40, and IA-N4PE Aβ42/40 (AUC range, 0.69-0.78; P Conclusions and relevance The results from 2 independent cohorts indicate that certain MS-based methods performed better than most of the immunoassays for plasma Aβ42/40 when detecting brain Aβ pathology. 2 key findings →
Participants: 182 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Atypical antipsychotic use is associated with an increased risk for death compared with nonuse among older adults with dementia. 5 key findings →
Design: cohort study Participants: 27,259 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Older adults with CVD other than stroke had a higher risk of dementia and AD than did those without CVD. 5 key findings →
Design: cohort study Participants: 3,602 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The ACR is approximately 5-10% and most people with MCI will not progress to dementia even after 10 years of follow-up. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Participation in leisure activities is associated with a reduced risk of dementia, even after adjustment for base-line cognitive status and after the exclusion of subjects with possible preclinical dementia. 5 key findings →
Design: prospective cohort Participants: 469 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
20 participants--15 in the AN1792 group, five in the placebo group--died before follow-up started. 2 key findings →
Participants: 80 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This review revealed a paucity of long-term studies on the relationship between physical activity and the incidence of NCD. 3 key findings →
Design: cross-sectional Participants: 288,724 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The study cohorts had an average age of 75.0 years (95% CI, 74.8-75.2 years) in 2000 and 74.8 years (95% CI, 74.5-75.1 years) in 2012 (P = .24); 58.4% (95% CI, 57.3%-59.4%) of the 2000 cohort was female compared with 56.3% (95% CI, 55.5%-57.0%) of the 2012 cohort (P Conclusions and relevance The prevalence of dementia in the United States declined significantly between 2000 and 2012. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Sensitivity analyses suggest that these estimates are robust to the change in response. 2 key findings →
Participants: 2,500 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Sleep dysregulation is a feature of dementia but it remains unclear whether sleep duration prior to old age is associated with dementia incidence. 4 key findings →
Participants: 7,959 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Using stratification with simply assessed markers, it is now not only possible, but practical to include patients with RBD in neuroprotective trials against Parkinson disease, multiple system atrophy, and dementia with Lewy bodies. 3 key findings →
Design: prospective cohort Participants: 89 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Patients who meet the criteria for MCI can be differentiated from healthy control subjects and those with very mild AD. 4 key findings →
Design: longitudinal study Participants: 106 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
High dietary intake of vitamin C and vitamin E may lower the risk of Alzheimer disease. 4 key findings →
Design: cohort study Participants: 5,395 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Between 2001, and 2012, we identified 243 611 incident cases of dementia, 31 577 cases of Parkinson's disease, and 9247 cases of multiple sclerosis. 3 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Neuropathology was ubiquitous, with 94% of participants having 1+, 78% having 2+, 58% having 3+, and 35% having 4+. 1 key finding →
Design: longitudinal study Participants: 1,079 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The highly consistent regional hierarchy of PET-evidenced amyloid deposition across participants resembles neuropathologic observations and suggests a predictable regional sequence that may be used to stage an individual's progress of amyloid pathology in vivo. 2 key findings →
Design: cross-sectional Participants: 667 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →